<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051661</url>
  </required_header>
  <id_info>
    <org_study_id>114000</org_study_id>
    <nct_id>NCT01051661</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age</brief_title>
  <official_title>A Study to Evaluate the Safety and Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children Aged 6 Months to Less Than 10 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and efficacy of GSK Biologicals' H1N1
      flu candidate vaccines GSK2340274A and GSK2340273A in children 6 months to less than 10 years
      of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2010</start_date>
  <completion_date type="Actual">September 9, 2011</completion_date>
  <primary_completion_date type="Actual">August 31, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting at Least One A/California Influenza Event</measure>
    <time_frame>From 14 days after first vaccination until study conclusion on Day 385</time_frame>
    <description>The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting at Least One A/California Influenza Event</measure>
    <time_frame>From 42 days after first vaccination until study conclusion on Day 385</time_frame>
    <description>The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting at Least One A/California Influenza Event</measure>
    <time_frame>From Day 0 until study conclusion on Day 385</time_frame>
    <description>The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event</measure>
    <time_frame>From 14 days after first vaccination until study conclusion on Day 385</time_frame>
    <description>The influenza virus presence was confirmed by a positive culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event</measure>
    <time_frame>From 42 days after first vaccination until study conclusion on Day 385</time_frame>
    <description>The influenza virus presence was confirmed by a positive culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event</measure>
    <time_frame>From Day 0 until study conclusion on Day 385</time_frame>
    <description>The influenza virus presence was confirmed by a positive culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Pneumonia Event</measure>
    <time_frame>From 14 days after first vaccination until study conclusion on Day 385</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Pneumonia Event</measure>
    <time_frame>From 42 days after first vaccination until study conclusion on Day 385</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Pneumonia Event</measure>
    <time_frame>From Day 0 after first vaccination until study conclusion on Day 385</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Pneumonia Event</measure>
    <time_frame>From 14 days after first vaccination until study conclusion at Day 385</time_frame>
    <description>Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Pneumonia Event</measure>
    <time_frame>From 42 days after first vaccination until study conclusion at Day 385</time_frame>
    <description>Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Pneumonia Event</measure>
    <time_frame>From Day 0 after first vaccination until study conclusion at Day 385</time_frame>
    <description>Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Protocol Specified Influenza-like Illness (ILI) Symptoms in All Reported ILI Cases</measure>
    <time_frame>From Day 0 until study end at Day 385</time_frame>
    <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Protocol Specified Influenza-like Illness (ILI) Symptoms in All Reported ILI Cases</measure>
    <time_frame>From Day 14 until study end at Day 385</time_frame>
    <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue. Analysis for the time frame Day 42 till Day 385 was not performed as planned per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Protocol Specified ILI Symptoms in RT-qPCR-confirmed A/California Influenza Cases</measure>
    <time_frame>From Day 0 until study end at Day 385</time_frame>
    <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Protocol Specified ILI Symptoms in RT-qPCR-confirmed A/California Influenza Cases</measure>
    <time_frame>From Day 14 until study end at Day 385</time_frame>
    <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue. Analysis for the time frame Day 42 till Day 385 was not performed as planned per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 7-day follow-up period (Day 0 - Day 6) after each dose and across doses</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Children Aged 6 Months to Less Than 6 Years</measure>
    <time_frame>During the 7-day follow-up period (Day 0 - Day 6) after each dose and across doses</time_frame>
    <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 drowsiness = drowsiness which prevented normal everyday activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 temperature = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Children Aged Between 6 to 10 Years</measure>
    <time_frame>During the 7-day follow-up period (Day 0 - Day 6) after each dose and across doses</time_frame>
    <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (gastro.sympt.), headache, joint pain at other location, muscle aches, shivering, sweating and temperature [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)]. Any = Incidence of a particular symptom regardless of intensity grade or relationship to study vaccination. Grade 3 = symptom which prevented normal everyday activity. Grade 3 temperature = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)</measure>
    <time_frame>Up to Day 385</time_frame>
    <description>Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Medically-attended Adverse Events (MAEs)</measure>
    <time_frame>Up to Day 385</time_frame>
    <description>MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs)</measure>
    <time_frame>From Day 0 to Day 42</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 385</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Days 0 and 42</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Days 0 and 42</time_frame>
    <description>A seropositive subject was defined as a subject whose HI titers were greater than or equal to (≥) 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>Seroconversion was defined as: for initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Days 0 and 42</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post-vaccination compared to Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titer Ratio Adjusted for Baseline Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1)</measure>
    <time_frame>At Day 42</time_frame>
    <description>The geometric mean titer ratio (GMT ratio) was defined as the ratio of geometric mean of the post-vaccination reciprocal HI titer between groups. The analysis was not performed for Day 182 and Day 385 as planned per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1)</measure>
    <time_frame>At Days 0 and 182</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Days 0 and 182</time_frame>
    <description>A seropositive subject was defined as a subject whose HI titers were greater than or equal to (≥) 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Day 182</time_frame>
    <description>Seroconversion was defined as: for initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Days 0 and 182</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Day 182</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Days 0 and 385</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Days 0 and 385</time_frame>
    <description>A seropositive subject was defined as a subject whose HI titers was greater than or equal to (≥) 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Day 385</time_frame>
    <description>Seroconversion was defined as: for initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Days 0 and 385</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</measure>
    <time_frame>At Day 385</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">6154</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Arepanrix 2D 6M-3Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arepanrix 2D 3Y-10Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arepanrix 1D 6M-3Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arepanrix 1D 3Y-10Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2340273A 6M-3Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2340273A 3Y-10Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)</intervention_name>
    <description>Intramuscular injection, one or two doses</description>
    <arm_group_label>Arepanrix 1D 3Y-10Y Group</arm_group_label>
    <arm_group_label>Arepanrix 1D 6M-3Y Group</arm_group_label>
    <arm_group_label>Arepanrix 2D 3Y-10Y Group</arm_group_label>
    <arm_group_label>Arepanrix 2D 6M-3Y Group</arm_group_label>
    <other_name>Arepanrix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)</intervention_name>
    <description>Intramuscular injection, two doses</description>
    <arm_group_label>GSK2340273A 3Y-10Y Group</arm_group_label>
    <arm_group_label>GSK2340273A 6M-3Y Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection, one dose</description>
    <arm_group_label>Arepanrix 1D 3Y-10Y Group</arm_group_label>
    <arm_group_label>Arepanrix 1D 6M-3Y Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female children 6 months to less than 10 years of age at the time of the first
             vaccination. &quot;Less than 10 years of age&quot; implies inclusion of children who have not
             reached their 10th birthday as of Day 0, the day of first vaccine dose under this
             protocol.

          -  Written informed consent obtained from the subject's parent(s)/legally acceptable
             representative(s) (LAR(s)); written informed assent obtained from the subject if
             appropriate pre local requirements).

          -  Stable health status as defined by absence of a health event satisfying the definition
             of a SAE, or a change in an ongoing drug therapy due to therapeutic failure or
             symptoms of drug toxicity, within 1 month prior to enrolment.

          -  Parent(s)/LAR(s) available and accessible for active surveillance contacts.

          -  Parent(s)/LAR(s) and (if age-appropriate, subjects) who, in the investigator's
             opinion, can and will comply with the requirements of the protocol as documented by
             signature on the informed consent document.

          -  Female subjects of non-childbearing potential (pre-menarche) may be enrolled in the
             study.

        Exclusion Criteria:

          -  Previous vaccination with an A/California/7/2009 (H1N1)v-like virus vaccine.

          -  Medical history of physician-confirmed infection with an A/California/7/2009
             (H1N1)v-like virus.

          -  Presence of evidence of substance abuse or of neurological or psychiatric diagnoses
             which, even if stable, are deemed by the investigator to render the potential subject
             or parent(s)/LAR(s) unable/unlikely to provide accurate safety reports.

          -  Presence of a temperature ≥ 38.0ºC (≥ 100.4ºF) by any route or method, or acute
             symptoms greater than &quot;mild&quot; severity on the scheduled date of first vaccination.
             NOTE: The subject may be vaccinated at a later date, provided symptoms have resolved,
             vaccination occurs within the window specified by the protocol, and all other
             eligibility criteria continue to be satisfied.

          -  Diagnosed with cancer, or treatment for cancer, within 3 years.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination (no laboratory testing required).

          -  Receipt of systemic glucocorticoids within 1 month prior to study enrollment (first
             dose of study vaccine), or any other cytotoxic or immunosuppressive drug within 6
             months of study enrollment. Topical, intra-articular or inhaled glucocorticoids are
             allowed.

          -  Receipt of any immunoglobulins and/or any blood products within 6 months of study
             enrollment or planned administration of any of these products during the study period.

          -  Any significant disorder of coagulation or treatment with warfarin derivatives or
             heparin. Persons receiving individual doses of low molecular weight heparin are
             eligible if no such doses are given in the 24 hours before a study vaccination.
             Persons receiving prophylactic antiplatelet medications, e.g., low-dose
             acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are
             eligible.

          -  An acute evolving neurological disorder or history of Guillain-Barré syndrome within 6
             weeks of receipt of seasonal influenza vaccine.

          -  Administration of any licensed live attenuated vaccine within 4 weeks before the first
             vaccination or of any licensed inactivated vaccine within 2 weeks before the first
             vaccination.

          -  Planned administration of any vaccine not foreseen by the study protocol between Day 0
             and Day 42. Routine childhood vaccinations are exempted if they cannot be delayed, but
             they must not be administered on the same day as the H1N1 vaccine candidate.

          -  Planned use of a pandemic monovalent A/California/7/2009 (H1N1)v-like virus vaccine
             other than the study vaccines during the study period.

          -  Planned administration of seasonal trivalent influenza vaccine during the 4 month
             period following Day 0.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days before the first dose of study vaccine, or planned use
             during the study period.

          -  Any known or suspected allergy to any constituent of influenza vaccines (including egg
             proteins or mercurial preservatives); a history of anaphylactic-type reaction to
             consumption of eggs; or a history of severe adverse reaction to a previous influenza
             vaccine.

          -  Child in care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kippa Ring</city>
        <state>Queensland</state>
        <zip>4021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Florianópolis</city>
        <state>Santa Catarina</state>
        <zip>88025 300</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04038 001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>3400</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico city</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dasmariñas, Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sampaloc, Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>768826</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
    <country>India</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MA, Cruz-Valdez A, Litao S, Lim FS, de Los Santos AM, Weber MA, Tinoco JC, Mezerville MH, Faingezicht I, Kosuwon P, Lopez P, Borja-Tabora C, Li P, Durviaux S, Fries L, Dubin G, Breuer T, Innis BL, Vaughn DW. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J Infect Dis. 2014 Aug 15;210(4):545-57. doi: 10.1093/infdis/jiu173. Epub 2014 Mar 20.</citation>
    <PMID>24652494</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <results_first_submitted>August 25, 2017</results_first_submitted>
  <results_first_submitted_qc>April 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2020</results_first_posted>
  <disposition_first_submitted>November 10, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>November 10, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 16, 2011</disposition_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>H1N1</keyword>
  <keyword>Pandemic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (click on the link provided below)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114000</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114000</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114000</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114000</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114000</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114000</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arepanrix 2D 6M-3Y Group</title>
          <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
        </group>
        <group group_id="P2">
          <title>Arepanrix 2D 3Y-10Y Group</title>
          <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
        </group>
        <group group_id="P3">
          <title>Arepanrix 1D 6M-3Y Group</title>
          <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
        </group>
        <group group_id="P4">
          <title>Arepanrix 1D 3Y-10Y Group</title>
          <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
        </group>
        <group group_id="P5">
          <title>GSK2340273A 6M-3Y Group</title>
          <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
        </group>
        <group group_id="P6">
          <title>GSK2340273A 3Y-10Y Group</title>
          <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="610"/>
                <participants group_id="P2" count="1438"/>
                <participants group_id="P3" count="612"/>
                <participants group_id="P4" count="1436"/>
                <participants group_id="P5" count="613"/>
                <participants group_id="P6" count="1436"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="576"/>
                <participants group_id="P2" count="1375"/>
                <participants group_id="P3" count="573"/>
                <participants group_id="P4" count="1380"/>
                <participants group_id="P5" count="578"/>
                <participants group_id="P6" count="1369"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="35"/>
                <participants group_id="P6" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused blood sampling</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data not reliable</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to attend visit(s)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent not received from both parents</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to comply with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject lost legal representation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arepanrix 2D 6M-3Y Group</title>
          <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
        </group>
        <group group_id="B2">
          <title>Arepanrix 2D 3Y-10Y Group</title>
          <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
        </group>
        <group group_id="B3">
          <title>Arepanrix 1D 6M-3Y Group</title>
          <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
        </group>
        <group group_id="B4">
          <title>Arepanrix 1D 3Y-10Y Group</title>
          <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
        </group>
        <group group_id="B5">
          <title>GSK2340273A 6M-3Y Group</title>
          <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
        </group>
        <group group_id="B6">
          <title>GSK2340273A 3Y-10Y Group</title>
          <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="610"/>
            <count group_id="B2" value="1438"/>
            <count group_id="B3" value="612"/>
            <count group_id="B4" value="1436"/>
            <count group_id="B5" value="613"/>
            <count group_id="B6" value="1436"/>
            <count group_id="B7" value="6145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="8.8"/>
                    <measurement group_id="B2" value="73.4" spread="23.8"/>
                    <measurement group_id="B3" value="21.2" spread="8.8"/>
                    <measurement group_id="B4" value="73.2" spread="24.2"/>
                    <measurement group_id="B5" value="21.2" spread="8.6"/>
                    <measurement group_id="B6" value="73.2" spread="24.3"/>
                    <measurement group_id="B7" value="57.7" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="688"/>
                    <measurement group_id="B3" value="308"/>
                    <measurement group_id="B4" value="748"/>
                    <measurement group_id="B5" value="291"/>
                    <measurement group_id="B6" value="732"/>
                    <measurement group_id="B7" value="3058"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="319"/>
                    <measurement group_id="B2" value="750"/>
                    <measurement group_id="B3" value="304"/>
                    <measurement group_id="B4" value="688"/>
                    <measurement group_id="B5" value="322"/>
                    <measurement group_id="B6" value="704"/>
                    <measurement group_id="B7" value="3087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African Heritage/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="507"/>
                    <measurement group_id="B3" value="301"/>
                    <measurement group_id="B4" value="503"/>
                    <measurement group_id="B5" value="297"/>
                    <measurement group_id="B6" value="499"/>
                    <measurement group_id="B7" value="2404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White-Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White-Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="161"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="165"/>
                    <measurement group_id="B7" value="693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="731"/>
                    <measurement group_id="B3" value="246"/>
                    <measurement group_id="B4" value="745"/>
                    <measurement group_id="B5" value="243"/>
                    <measurement group_id="B6" value="734"/>
                    <measurement group_id="B7" value="2934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting at Least One A/California Influenza Event</title>
        <description>The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
        <time_frame>From 14 days after first vaccination until study conclusion on Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting at Least One A/California Influenza Event</title>
          <description>The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evaluation of the relative protective efficacy of 2 doses of Arepanrix™ vaccine (Arepanrix 2D Group) compared to two doses of GSK2340273A vaccine (GSK2340273A Group) beginning 14 days after Dose 1 vaccination (for each subject enrolled) and continuing until study conclusion on Day 385.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority objective was met if the lower limit (LL) of the 95% CI for the Vaccine Efficacy Improvement (VEI) was &gt; -33%. Furthermore, the superiority objective was met if the LL of the 95% CI for the VEI was &gt;0.</non_inferiority_desc>
            <param_type>Vaccine efficacy increase</param_type>
            <param_value>76.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.53</ci_lower_limit>
            <ci_upper_limit>93.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting at Least One A/California Influenza Event</title>
        <description>The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
        <time_frame>From 42 days after first vaccination until study conclusion on Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting at Least One A/California Influenza Event</title>
          <description>The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting at Least One A/California Influenza Event</title>
        <description>The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
        <time_frame>From Day 0 until study conclusion on Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting at Least One A/California Influenza Event</title>
          <description>The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event</title>
        <description>The influenza virus presence was confirmed by a positive culture.</description>
        <time_frame>From 14 days after first vaccination until study conclusion on Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event</title>
          <description>The influenza virus presence was confirmed by a positive culture.</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event</title>
        <description>The influenza virus presence was confirmed by a positive culture.</description>
        <time_frame>From 42 days after first vaccination until study conclusion on Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event</title>
          <description>The influenza virus presence was confirmed by a positive culture.</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event</title>
        <description>The influenza virus presence was confirmed by a positive culture.</description>
        <time_frame>From Day 0 until study conclusion on Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event</title>
          <description>The influenza virus presence was confirmed by a positive culture.</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Pneumonia Event</title>
        <time_frame>From 14 days after first vaccination until study conclusion on Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Pneumonia Event</title>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Pneumonia Event</title>
        <time_frame>From 42 days after first vaccination until study conclusion on Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Pneumonia Event</title>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Pneumonia Event</title>
        <time_frame>From Day 0 after first vaccination until study conclusion on Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Pneumonia Event</title>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Pneumonia Event</title>
        <description>Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
        <time_frame>From 14 days after first vaccination until study conclusion at Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Pneumonia Event</title>
          <description>Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Pneumonia Event</title>
        <description>Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
        <time_frame>From 42 days after first vaccination until study conclusion at Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Pneumonia Event</title>
          <description>Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Pneumonia Event</title>
        <description>Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
        <time_frame>From Day 0 after first vaccination until study conclusion at Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Pneumonia Event</title>
          <description>Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1940"/>
                <count group_id="O2" value="1933"/>
                <count group_id="O3" value="1930"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Protocol Specified Influenza-like Illness (ILI) Symptoms in All Reported ILI Cases</title>
        <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue.</description>
        <time_frame>From Day 0 until study end at Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Protocol Specified Influenza-like Illness (ILI) Symptoms in All Reported ILI Cases</title>
          <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue.</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1903"/>
                <count group_id="O2" value="1913"/>
                <count group_id="O3" value="1897"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="745"/>
                    <measurement group_id="O2" value="685"/>
                    <measurement group_id="O3" value="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches all over body</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="219"/>
                    <measurement group_id="O3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668"/>
                    <measurement group_id="O2" value="626"/>
                    <measurement group_id="O3" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="362"/>
                    <measurement group_id="O3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny or stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="682"/>
                    <measurement group_id="O2" value="628"/>
                    <measurement group_id="O3" value="649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Short of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="227"/>
                    <measurement group_id="O3" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360"/>
                    <measurement group_id="O2" value="340"/>
                    <measurement group_id="O3" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="265"/>
                    <measurement group_id="O3" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="265"/>
                    <measurement group_id="O3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="314"/>
                    <measurement group_id="O3" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Protocol Specified Influenza-like Illness (ILI) Symptoms in All Reported ILI Cases</title>
        <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue. Analysis for the time frame Day 42 till Day 385 was not performed as planned per protocol.</description>
        <time_frame>From Day 14 until study end at Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Protocol Specified Influenza-like Illness (ILI) Symptoms in All Reported ILI Cases</title>
          <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue. Analysis for the time frame Day 42 till Day 385 was not performed as planned per protocol.</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1903"/>
                <count group_id="O2" value="1913"/>
                <count group_id="O3" value="1897"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="716"/>
                    <measurement group_id="O2" value="659"/>
                    <measurement group_id="O3" value="677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches all over body</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="643"/>
                    <measurement group_id="O2" value="599"/>
                    <measurement group_id="O3" value="614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382"/>
                    <measurement group_id="O2" value="351"/>
                    <measurement group_id="O3" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny or stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="656"/>
                    <measurement group_id="O2" value="605"/>
                    <measurement group_id="O3" value="627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Short of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="218"/>
                    <measurement group_id="O3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348"/>
                    <measurement group_id="O2" value="329"/>
                    <measurement group_id="O3" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="254"/>
                    <measurement group_id="O3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="137"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                    <measurement group_id="O2" value="255"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340"/>
                    <measurement group_id="O2" value="302"/>
                    <measurement group_id="O3" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Protocol Specified ILI Symptoms in RT-qPCR-confirmed A/California Influenza Cases</title>
        <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue.</description>
        <time_frame>From Day 0 until study end at Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Protocol Specified ILI Symptoms in RT-qPCR-confirmed A/California Influenza Cases</title>
          <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue.</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1903"/>
                <count group_id="O2" value="1913"/>
                <count group_id="O3" value="1897"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches all over body</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny or stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Short of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Protocol Specified ILI Symptoms in RT-qPCR-confirmed A/California Influenza Cases</title>
        <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue. Analysis for the time frame Day 42 till Day 385 was not performed as planned per protocol.</description>
        <time_frame>From Day 14 until study end at Day 385</time_frame>
        <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Protocol Specified ILI Symptoms in RT-qPCR-confirmed A/California Influenza Cases</title>
          <description>Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue. Analysis for the time frame Day 42 till Day 385 was not performed as planned per protocol.</description>
          <population>The analyses were performed on the According-to-Protocol (ATP) cohort for analysis of efficacy, which included all eligible subjects, who received the study vaccine/placebo according to their treatment assignment, and for whom efficacy data were available. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1903"/>
                <count group_id="O2" value="1913"/>
                <count group_id="O3" value="1897"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches all over body</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny or stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Short of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
        <time_frame>During the 7-day follow-up period (Day 0 - Day 6) after each dose and across doses</time_frame>
        <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, from the age strata groups, who received at least 1 dose of study vaccine and who filled in their symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to less than (&lt;) 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-6Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to less than (&lt;) 6 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 2D 6Y-10Y Group</title>
            <description>Subjects, male and female, aged 6 years (Y) to less than (&lt;) 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to less than (&lt;) 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O5">
            <title>Arepanrix 1D 3Y-6Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to less than (&lt;) 6 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix 1D 6Y-10Y Group</title>
            <description>Subjects, male and female, aged 6 years (Y) to less than (&lt;) 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to less than (&lt;) 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A 3Y-6Y Group</title>
            <description>Subjects, male and female, aged 2 years (Y) to less than (&lt;) 6 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O9">
            <title>GSK2340273A 6Y-10Y Group</title>
            <description>Subjects, male and female, aged 6 years (Y) to less than (&lt;) 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
          <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, from the age strata groups, who received at least 1 dose of study vaccine and who filled in their symptom sheets.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="726"/>
                <count group_id="O3" value="712"/>
                <count group_id="O4" value="612"/>
                <count group_id="O5" value="744"/>
                <count group_id="O6" value="692"/>
                <count group_id="O7" value="613"/>
                <count group_id="O8" value="714"/>
                <count group_id="O9" value="722"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="369"/>
                    <measurement group_id="O3" value="416"/>
                    <measurement group_id="O4" value="189"/>
                    <measurement group_id="O5" value="357"/>
                    <measurement group_id="O6" value="409"/>
                    <measurement group_id="O7" value="122"/>
                    <measurement group_id="O8" value="212"/>
                    <measurement group_id="O9" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="591"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="681"/>
                    <count group_id="O7" value="593"/>
                    <count group_id="O8" value="696"/>
                    <count group_id="O9" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="344"/>
                    <measurement group_id="O3" value="347"/>
                    <measurement group_id="O4" value="104"/>
                    <measurement group_id="O5" value="153"/>
                    <measurement group_id="O6" value="133"/>
                    <measurement group_id="O7" value="86"/>
                    <measurement group_id="O8" value="157"/>
                    <measurement group_id="O9" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="591"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="681"/>
                    <count group_id="O7" value="593"/>
                    <count group_id="O8" value="696"/>
                    <count group_id="O9" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="591"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="681"/>
                    <count group_id="O7" value="593"/>
                    <count group_id="O8" value="696"/>
                    <count group_id="O9" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="591"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="681"/>
                    <count group_id="O7" value="593"/>
                    <count group_id="O8" value="696"/>
                    <count group_id="O9" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="591"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="681"/>
                    <count group_id="O7" value="593"/>
                    <count group_id="O8" value="696"/>
                    <count group_id="O9" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="591"/>
                    <count group_id="O5" value="727"/>
                    <count group_id="O6" value="681"/>
                    <count group_id="O7" value="593"/>
                    <count group_id="O8" value="696"/>
                    <count group_id="O9" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="454"/>
                    <measurement group_id="O3" value="487"/>
                    <measurement group_id="O4" value="222"/>
                    <measurement group_id="O5" value="382"/>
                    <measurement group_id="O6" value="431"/>
                    <measurement group_id="O7" value="154"/>
                    <measurement group_id="O8" value="258"/>
                    <measurement group_id="O9" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="712"/>
                    <count group_id="O4" value="612"/>
                    <count group_id="O5" value="744"/>
                    <count group_id="O6" value="692"/>
                    <count group_id="O7" value="613"/>
                    <count group_id="O8" value="714"/>
                    <count group_id="O9" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Children Aged 6 Months to Less Than 6 Years</title>
        <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 drowsiness = drowsiness which prevented normal everyday activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 temperature = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 7-day follow-up period (Day 0 - Day 6) after each dose and across doses</time_frame>
        <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, from the age strata groups, who received at least 1 dose of study vaccine and who filled in their symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to less than (&lt;) 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-6Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to less than (&lt;) 6 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to less than (&lt;) 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-6Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to less than (&lt;) 6 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to less than (&lt;) 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-6Y Group</title>
            <description>Subjects, male and female, aged 2 years (Y) to less than (&lt;) 6 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Children Aged 6 Months to Less Than 6 Years</title>
          <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 drowsiness = drowsiness which prevented normal everyday activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 temperature = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, from the age strata groups, who received at least 1 dose of study vaccine and who filled in their symptom sheets.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="726"/>
                <count group_id="O3" value="612"/>
                <count group_id="O4" value="744"/>
                <count group_id="O5" value="613"/>
                <count group_id="O6" value="714"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="112"/>
                    <measurement group_id="O5" value="106"/>
                    <measurement group_id="O6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="56"/>
                    <measurement group_id="O6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="111"/>
                    <measurement group_id="O5" value="135"/>
                    <measurement group_id="O6" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="83"/>
                    <measurement group_id="O6" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="116"/>
                    <measurement group_id="O6" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="63"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="73"/>
                    <measurement group_id="O6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="104"/>
                    <measurement group_id="O6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="64"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="102"/>
                    <measurement group_id="O6" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="56"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="727"/>
                    <count group_id="O5" value="593"/>
                    <count group_id="O6" value="696"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="137"/>
                    <measurement group_id="O5" value="149"/>
                    <measurement group_id="O6" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="164"/>
                    <measurement group_id="O4" value="139"/>
                    <measurement group_id="O5" value="190"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="109"/>
                    <measurement group_id="O5" value="121"/>
                    <measurement group_id="O6" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="134"/>
                    <measurement group_id="O5" value="175"/>
                    <measurement group_id="O6" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="109"/>
                    <measurement group_id="O6" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="726"/>
                    <count group_id="O3" value="612"/>
                    <count group_id="O4" value="744"/>
                    <count group_id="O5" value="613"/>
                    <count group_id="O6" value="714"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Children Aged Between 6 to 10 Years</title>
        <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (gastro.sympt.), headache, joint pain at other location, muscle aches, shivering, sweating and temperature [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)]. Any = Incidence of a particular symptom regardless of intensity grade or relationship to study vaccination. Grade 3 = symptom which prevented normal everyday activity. Grade 3 temperature = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 7-day follow-up period (Day 0 - Day 6) after each dose and across doses</time_frame>
        <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, from the age strata groups, who received at least 1 dose of study vaccine and who filled in their symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6Y-10Y Group</title>
            <description>Subjects, male and female, aged 6 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D 6Y-10Y Group</title>
            <description>Subjects, male and female, aged 6 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A 6Y-10Y Group</title>
            <description>Subjects, male and female, aged 6 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Children Aged Between 6 to 10 Years</title>
          <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (gastro.sympt.), headache, joint pain at other location, muscle aches, shivering, sweating and temperature [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)]. Any = Incidence of a particular symptom regardless of intensity grade or relationship to study vaccination. Grade 3 = symptom which prevented normal everyday activity. Grade 3 temperature = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, from the age strata groups, who received at least 1 dose of study vaccine and who filled in their symptom sheets.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="692"/>
                <count group_id="O3" value="722"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastro.sympt., Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastro.sympt., Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastro.sympt., Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="129"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Joint pain at other location, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Joint pain at other location, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Joint pain at other location, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle aches, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle aches, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Muscle aches, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastro.sympt., Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastro.sympt., Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastro.sympt., Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Joint pain at other location, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Joint pain at other location, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Joint pain at other location, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle aches, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle aches, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Muscle aches, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="699"/>
                    <count group_id="O2" value="681"/>
                    <count group_id="O3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastro.sympt., Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastro.sympt., Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastro.sympt., Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Joint pain at other location, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Joint pain at other location, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Joint pain at other location, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle aches, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle aches, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Muscle aches, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="712"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="722"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)</title>
        <description>Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
        <time_frame>Up to Day 385</time_frame>
        <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, who received at least 1 dose of study vaccine and who filled in their symptom sheets. This analysis compared the different treatment groups based on the type of vaccine received.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)</title>
          <description>Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
          <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, who received at least 1 dose of study vaccine and who filled in their symptom sheets. This analysis compared the different treatment groups based on the type of vaccine received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2048"/>
                <count group_id="O2" value="2048"/>
                <count group_id="O3" value="2049"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Medically-attended Adverse Events (MAEs)</title>
        <description>MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.</description>
        <time_frame>Up to Day 385</time_frame>
        <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, who received at least 1 dose of study vaccine and who filled in their symptom sheets. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Medically-attended Adverse Events (MAEs)</title>
          <description>MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.</description>
          <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, who received at least 1 dose of study vaccine and who filled in their symptom sheets. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2048"/>
                <count group_id="O2" value="2048"/>
                <count group_id="O3" value="2049"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1189"/>
                    <measurement group_id="O2" value="1173"/>
                    <measurement group_id="O3" value="1190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>From Day 0 to Day 42</time_frame>
        <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, who received at least 1 dose of study vaccine and who filled in their symptom sheets. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
          <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, who received at least 1 dose of study vaccine and who filled in their symptom sheets. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2048"/>
                <count group_id="O2" value="2048"/>
                <count group_id="O3" value="2049"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="913"/>
                    <measurement group_id="O2" value="904"/>
                    <measurement group_id="O3" value="895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>Up to Day 385</time_frame>
        <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, who received at least 1 dose of study vaccine and who filled in their symptom sheets. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analyses were performed on the Total Vaccinated cohort, which included all subjects, who received at least 1 dose of study vaccine and who filled in their symptom sheets. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2048"/>
                <count group_id="O2" value="2048"/>
                <count group_id="O3" value="2049"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>Titers are presented as geometric mean titers (GMTs).</description>
        <time_frame>At Days 0 and 42</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects with both doses of study vaccine/placebo administered per protocol treatment assignment and assay results for antibodies against A/California at the relevant timepoints were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>Titers are presented as geometric mean titers (GMTs).</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects with both doses of study vaccine/placebo administered per protocol treatment assignment and assay results for antibodies against A/California at the relevant timepoints were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="232"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="223"/>
                <count group_id="O6" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="228"/>
                    <count group_id="O4" value="153"/>
                    <count group_id="O5" value="220"/>
                    <count group_id="O6" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.40" lower_limit="10.21" upper_limit="15.06"/>
                    <measurement group_id="O2" value="16.92" lower_limit="13.77" upper_limit="20.80"/>
                    <measurement group_id="O3" value="11.19" lower_limit="9.32" upper_limit="13.43"/>
                    <measurement group_id="O4" value="14.17" lower_limit="11.48" upper_limit="17.49"/>
                    <measurement group_id="O5" value="12.25" lower_limit="9.97" upper_limit="15.07"/>
                    <measurement group_id="O6" value="14.76" lower_limit="12.04" upper_limit="18.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="232"/>
                    <count group_id="O4" value="156"/>
                    <count group_id="O5" value="223"/>
                    <count group_id="O6" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1738.90" lower_limit="1598.65" upper_limit="1891.44"/>
                    <measurement group_id="O2" value="1345.36" lower_limit="1228.32" upper_limit="1473.55"/>
                    <measurement group_id="O3" value="258.02" lower_limit="219.86" upper_limit="302.79"/>
                    <measurement group_id="O4" value="279.52" lower_limit="229.58" upper_limit="340.31"/>
                    <measurement group_id="O5" value="188.89" lower_limit="156.13" upper_limit="228.53"/>
                    <measurement group_id="O6" value="443.98" lower_limit="367.03" upper_limit="537.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>A seropositive subject was defined as a subject whose HI titers were greater than or equal to (≥) 1:10.</description>
        <time_frame>At Days 0 and 42</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects with both doses of study vaccine/placebo administered per protocol treatment assignment and assay results for antibodies against A/California at the relevant timepoints were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>A seropositive subject was defined as a subject whose HI titers were greater than or equal to (≥) 1:10.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects with both doses of study vaccine/placebo administered per protocol treatment assignment and assay results for antibodies against A/California at the relevant timepoints were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="232"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="223"/>
                <count group_id="O6" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="228"/>
                    <count group_id="O4" value="153"/>
                    <count group_id="O5" value="220"/>
                    <count group_id="O6" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="69"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="232"/>
                    <count group_id="O4" value="156"/>
                    <count group_id="O5" value="223"/>
                    <count group_id="O6" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="232"/>
                    <measurement group_id="O4" value="156"/>
                    <measurement group_id="O5" value="220"/>
                    <measurement group_id="O6" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>Seroconversion was defined as: for initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.</description>
        <time_frame>At Day 42</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>Seroconversion was defined as: for initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoints.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="153"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="166"/>
                    <measurement group_id="O3" value="224"/>
                    <measurement group_id="O4" value="149"/>
                    <measurement group_id="O5" value="187"/>
                    <measurement group_id="O6" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
        <time_frame>At Days 0 and 42</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects with both doses of study vaccine/placebo administered per protocol treatment assignment and assay results for antibodies against A/California at the relevant timepoints were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects with both doses of study vaccine/placebo administered per protocol treatment assignment and assay results for antibodies against A/California at the relevant timepoints were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="232"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="223"/>
                <count group_id="O6" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="228"/>
                    <count group_id="O4" value="153"/>
                    <count group_id="O5" value="220"/>
                    <count group_id="O6" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="55"/>
                    <measurement group_id="O6" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="232"/>
                    <count group_id="O4" value="156"/>
                    <count group_id="O5" value="223"/>
                    <count group_id="O6" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="229"/>
                    <measurement group_id="O4" value="154"/>
                    <measurement group_id="O5" value="199"/>
                    <measurement group_id="O6" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post-vaccination compared to Day 0.</description>
        <time_frame>At Day 42</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post-vaccination compared to Day 0.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoints.</population>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="153"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.8" lower_limit="116.6" upper_limit="170.0"/>
                    <measurement group_id="O2" value="79.9" lower_limit="65.3" upper_limit="97.6"/>
                    <measurement group_id="O3" value="23.4" lower_limit="21.2" upper_limit="25.7"/>
                    <measurement group_id="O4" value="20.3" lower_limit="17.7" upper_limit="23.3"/>
                    <measurement group_id="O5" value="15.6" lower_limit="13.5" upper_limit="18.0"/>
                    <measurement group_id="O6" value="29.9" lower_limit="25.1" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titer Ratio Adjusted for Baseline Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1)</title>
        <description>The geometric mean titer ratio (GMT ratio) was defined as the ratio of geometric mean of the post-vaccination reciprocal HI titer between groups. The analysis was not performed for Day 182 and Day 385 as planned per protocol.</description>
        <time_frame>At Day 42</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 1D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A Group</title>
            <description>Subjects, male and female, aged 6 months to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh. This group pooled the subjects from the 6M-3Y and 3Y-10Y age strata.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titer Ratio Adjusted for Baseline Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1)</title>
          <description>The geometric mean titer ratio (GMT ratio) was defined as the ratio of geometric mean of the post-vaccination reciprocal HI titer between groups. The analysis was not performed for Day 182 and Day 385 as planned per protocol.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 42, which included all evaluable subjects with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint. The groups were pooled, based on the type of vaccine received and regardless the age strata.</population>
          <units>Adjusted GMT ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="395"/>
                <count group_id="O3" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.9"/>
                    <measurement group_id="O2" value="1548.5"/>
                    <measurement group_id="O3" value="275.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjusted Geometric mean titer (GMT) ratios of Hemagglutination Inhibition (HI) antibody post vaccination between Arepanrix 2D Group and GSK2340273A Group for A/California influenza strain (Arepanrix 2D Group/GSK2340273A Group).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Adjusted GMT ratios</param_type>
            <param_value>5.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.92</ci_lower_limit>
            <ci_upper_limit>6.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjusted Geometric mean titer (GMT) ratios of Hemagglutination Inhibition (HI) antibody post vaccination between Arepanrix 1D Group and GSK2340273A Group for A/California influenza strain (Arepanrix 1D Group/GSK2340273A Group).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Adjusted GMT ratios</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1)</title>
        <description>Titers are presented as geometric mean titers (GMTs).</description>
        <time_frame>At Days 0 and 182</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1)</title>
          <description>Titers are presented as geometric mean titers (GMTs).</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="389"/>
                <count group_id="O5" value="184"/>
                <count group_id="O6" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.62" lower_limit="8.79" upper_limit="18.12"/>
                    <measurement group_id="O2" value="11.79" lower_limit="7.90" upper_limit="17.60"/>
                    <measurement group_id="O3" value="9.77" lower_limit="7.23" upper_limit="13.22"/>
                    <measurement group_id="O4" value="17.57" lower_limit="12.16" upper_limit="25.40"/>
                    <measurement group_id="O5" value="14.22" lower_limit="9.03" upper_limit="22.40"/>
                    <measurement group_id="O6" value="12.19" lower_limit="8.43" upper_limit="17.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 182</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="378"/>
                    <count group_id="O3" value="177"/>
                    <count group_id="O4" value="389"/>
                    <count group_id="O5" value="184"/>
                    <count group_id="O6" value="379"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.22" lower_limit="246.77" upper_limit="334.29"/>
                    <measurement group_id="O2" value="238.25" lower_limit="213.25" upper_limit="266.18"/>
                    <measurement group_id="O3" value="76.52" lower_limit="61.99" upper_limit="94.46"/>
                    <measurement group_id="O4" value="108.59" lower_limit="94.10" upper_limit="125.30"/>
                    <measurement group_id="O5" value="74.94" lower_limit="59.09" upper_limit="95.05"/>
                    <measurement group_id="O6" value="145.06" lower_limit="128.28" upper_limit="164.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>A seropositive subject was defined as a subject whose HI titers were greater than or equal to (≥) 1:10.</description>
        <time_frame>At Days 0 and 182</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>A seropositive subject was defined as a subject whose HI titers were greater than or equal to (≥) 1:10.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="389"/>
                <count group_id="O5" value="184"/>
                <count group_id="O6" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 182</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="378"/>
                    <count group_id="O3" value="177"/>
                    <count group_id="O4" value="389"/>
                    <count group_id="O5" value="184"/>
                    <count group_id="O6" value="379"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="378"/>
                    <measurement group_id="O3" value="177"/>
                    <measurement group_id="O4" value="384"/>
                    <measurement group_id="O5" value="174"/>
                    <measurement group_id="O6" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>Seroconversion was defined as: for initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.</description>
        <time_frame>At Day 182</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>Seroconversion was defined as: for initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
        <time_frame>At Days 0 and 182</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="389"/>
                <count group_id="O5" value="184"/>
                <count group_id="O6" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 182</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="378"/>
                    <count group_id="O3" value="177"/>
                    <count group_id="O4" value="389"/>
                    <count group_id="O5" value="184"/>
                    <count group_id="O6" value="379"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="374"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="288"/>
                    <measurement group_id="O5" value="117"/>
                    <measurement group_id="O6" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.</description>
        <time_frame>At Day 182</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 182, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="18.5" upper_limit="31.1"/>
                    <measurement group_id="O2" value="18.4" lower_limit="13.1" upper_limit="25.8"/>
                    <measurement group_id="O3" value="8.0" lower_limit="6.8" upper_limit="9.3"/>
                    <measurement group_id="O4" value="6.1" lower_limit="4.7" upper_limit="7.9"/>
                    <measurement group_id="O5" value="4.8" lower_limit="3.7" upper_limit="6.3"/>
                    <measurement group_id="O6" value="8.5" lower_limit="6.4" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>Titers are presented as geometric mean titers (GMTs).</description>
        <time_frame>At Days 0 and 385</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>Titers are presented as geometric mean titers (GMTs).</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="349"/>
                <count group_id="O3" value="163"/>
                <count group_id="O4" value="339"/>
                <count group_id="O5" value="158"/>
                <count group_id="O6" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.62" lower_limit="6.76" upper_limit="13.69"/>
                    <measurement group_id="O2" value="15.71" lower_limit="9.76" upper_limit="25.27"/>
                    <measurement group_id="O3" value="9.93" lower_limit="6.71" upper_limit="14.71"/>
                    <measurement group_id="O4" value="14.92" lower_limit="8.99" upper_limit="24.74"/>
                    <measurement group_id="O5" value="10.13" lower_limit="7.04" upper_limit="14.56"/>
                    <measurement group_id="O6" value="13.57" lower_limit="8.50" upper_limit="21.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 385</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="349"/>
                    <count group_id="O3" value="163"/>
                    <count group_id="O4" value="339"/>
                    <count group_id="O5" value="158"/>
                    <count group_id="O6" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.61" lower_limit="228.92" upper_limit="308.18"/>
                    <measurement group_id="O2" value="189.44" lower_limit="169.64" upper_limit="211.55"/>
                    <measurement group_id="O3" value="112.56" lower_limit="91.27" upper_limit="138.81"/>
                    <measurement group_id="O4" value="103.57" lower_limit="89.90" upper_limit="119.32"/>
                    <measurement group_id="O5" value="54.90" lower_limit="42.15" upper_limit="71.50"/>
                    <measurement group_id="O6" value="92.33" lower_limit="80.18" upper_limit="106.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>A seropositive subject was defined as a subject whose HI titers was greater than or equal to (≥) 1:10.</description>
        <time_frame>At Days 0 and 385</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>A seropositive subject was defined as a subject whose HI titers was greater than or equal to (≥) 1:10.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="349"/>
                <count group_id="O3" value="163"/>
                <count group_id="O4" value="339"/>
                <count group_id="O5" value="158"/>
                <count group_id="O6" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 385</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="349"/>
                    <count group_id="O3" value="163"/>
                    <count group_id="O4" value="339"/>
                    <count group_id="O5" value="158"/>
                    <count group_id="O6" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="349"/>
                    <measurement group_id="O3" value="163"/>
                    <measurement group_id="O4" value="334"/>
                    <measurement group_id="O5" value="142"/>
                    <measurement group_id="O6" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>Seroconversion was defined as: for initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.</description>
        <time_frame>At Day 385</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>Seroconversion was defined as: for initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
        <time_frame>At Days 0 and 385</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="349"/>
                <count group_id="O3" value="163"/>
                <count group_id="O4" value="339"/>
                <count group_id="O5" value="158"/>
                <count group_id="O6" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 385</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="349"/>
                    <count group_id="O3" value="163"/>
                    <count group_id="O4" value="339"/>
                    <count group_id="O5" value="158"/>
                    <count group_id="O6" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="339"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="266"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.</description>
        <time_frame>At Day 385</time_frame>
        <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arepanrix 2D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O2">
            <title>Arepanrix 2D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O3">
            <title>Arepanrix 1D 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O4">
            <title>Arepanrix 1D 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
          <group group_id="O5">
            <title>GSK2340273A 6M-3Y Group</title>
            <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340273A 3Y-10Y Group</title>
            <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.</description>
          <population>The analyses were performed on the According-to-protocol (ATP) cohort for immunogenicity - Day 385, which included all evaluable subjects from Arepanrix age strata groups and subjects from main GSK2340273A Group, with study vaccine/placebo administered per protocol and assay results available at the relevant timepoint.</population>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="20.0" upper_limit="35.3"/>
                    <measurement group_id="O2" value="13.7" lower_limit="9.9" upper_limit="19.0"/>
                    <measurement group_id="O3" value="8.5" lower_limit="6.5" upper_limit="11.0"/>
                    <measurement group_id="O4" value="6.3" lower_limit="4.2" upper_limit="9.4"/>
                    <measurement group_id="O5" value="3.7" lower_limit="2.8" upper_limit="4.7"/>
                    <measurement group_id="O6" value="6.1" lower_limit="4.2" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local/general symptoms during the 7-day post-vaccination period (Days 0-6), Unsolicited AEs during the 42-day post-vaccination (Days 0-41), SAEs during the entire study period (Day 0 - Day 385).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arepanrix 2D 6M-3Y Group</title>
          <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
        </group>
        <group group_id="E2">
          <title>Arepanrix 2D 3Y-10Y Group</title>
          <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
        </group>
        <group group_id="E3">
          <title>Arepanrix 1D 6M-3Y Group</title>
          <description>Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
        </group>
        <group group_id="E4">
          <title>Arepanrix 1D 3Y-10Y Group</title>
          <description>Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
        </group>
        <group group_id="E5">
          <title>GSK2340273A 6M-3Y Group</title>
          <description>Subjects, male and female, aged 6 months to 3 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children &lt;12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children &lt;12 months of age, in the right anterolateral thigh.</description>
        </group>
        <group group_id="E6">
          <title>GSK2340273A 3Y-10Y Group</title>
          <description>Subjects, male and female, aged 3 years to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1438"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="612"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="1436"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="613"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Rectal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="610"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1438"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="612"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="1436"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="613"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Hepatitis a</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="610"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1438"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="612"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1436"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="613"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pneumonia parainfluenzae viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1436"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Mechanical ventilation complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="1436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1438"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Nasal septum disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Sexual abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Subgaleal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="427" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="1047" subjects_at_risk="1438"/>
                <counts group_id="E3" subjects_affected="339" subjects_at_risk="612"/>
                <counts group_id="E4" subjects_affected="941" subjects_at_risk="1436"/>
                <counts group_id="E5" subjects_affected="332" subjects_at_risk="613"/>
                <counts group_id="E6" subjects_affected="758" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="77" subjects_affected="68" subjects_at_risk="1438"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E4" events="74" subjects_affected="66" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="82" subjects_affected="72" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="179" subjects_affected="139" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="133" subjects_affected="118" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="129" subjects_affected="106" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="417" subjects_affected="288" subjects_at_risk="610"/>
                <counts group_id="E2" events="1476" subjects_affected="941" subjects_at_risk="1438"/>
                <counts group_id="E3" events="293" subjects_affected="222" subjects_at_risk="612"/>
                <counts group_id="E4" events="1052" subjects_affected="813" subjects_at_risk="1436"/>
                <counts group_id="E5" events="208" subjects_affected="154" subjects_at_risk="613"/>
                <counts group_id="E6" events="836" subjects_affected="580" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="225" subjects_affected="198" subjects_at_risk="610"/>
                <counts group_id="E2" events="253" subjects_affected="234" subjects_at_risk="1438"/>
                <counts group_id="E3" events="132" subjects_affected="124" subjects_at_risk="612"/>
                <counts group_id="E4" events="150" subjects_affected="141" subjects_at_risk="1436"/>
                <counts group_id="E5" events="101" subjects_affected="97" subjects_at_risk="613"/>
                <counts group_id="E6" events="104" subjects_affected="96" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="35" subjects_affected="31" subjects_at_risk="610"/>
                <counts group_id="E2" events="95" subjects_affected="80" subjects_at_risk="1438"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="612"/>
                <counts group_id="E4" events="54" subjects_affected="49" subjects_at_risk="1436"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="613"/>
                <counts group_id="E6" events="38" subjects_affected="31" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="221" subjects_affected="182" subjects_at_risk="610"/>
                <counts group_id="E2" events="202" subjects_affected="170" subjects_at_risk="1438"/>
                <counts group_id="E3" events="150" subjects_affected="126" subjects_at_risk="612"/>
                <counts group_id="E4" events="164" subjects_affected="134" subjects_at_risk="1436"/>
                <counts group_id="E5" events="218" subjects_affected="175" subjects_at_risk="613"/>
                <counts group_id="E6" events="135" subjects_affected="115" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="124" subjects_affected="102" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="100" subjects_affected="92" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="68" subjects_affected="61" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="210" subjects_affected="165" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="164" subjects_affected="140" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="113" subjects_affected="98" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="289" subjects_affected="231" subjects_at_risk="1438"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E4" events="204" subjects_affected="170" subjects_at_risk="1436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E6" events="183" subjects_affected="158" subjects_at_risk="1436"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="220" subjects_affected="175" subjects_at_risk="610"/>
                <counts group_id="E2" events="195" subjects_affected="160" subjects_at_risk="1438"/>
                <counts group_id="E3" events="146" subjects_affected="124" subjects_at_risk="612"/>
                <counts group_id="E4" events="170" subjects_affected="137" subjects_at_risk="1436"/>
                <counts group_id="E5" events="179" subjects_affected="149" subjects_at_risk="613"/>
                <counts group_id="E6" events="160" subjects_affected="133" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="313" subjects_affected="237" subjects_at_risk="610"/>
                <counts group_id="E2" events="194" subjects_affected="160" subjects_at_risk="1438"/>
                <counts group_id="E3" events="209" subjects_affected="164" subjects_at_risk="612"/>
                <counts group_id="E4" events="174" subjects_affected="139" subjects_at_risk="1436"/>
                <counts group_id="E5" events="239" subjects_affected="190" subjects_at_risk="613"/>
                <counts group_id="E6" events="115" subjects_affected="95" subjects_at_risk="1436"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

